Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926120 · ClinicalTrials.gov registry record · Phase 2
The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC
A Phase 2 study, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00926120 is a Phase 2 study that has completed, run by Brooke Army Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00926120, a Phase 2 study, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.
Interventions
- DIETARY_SUPPLEMENT Mogroside sweetener (PureLo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926120
The ClinicalTrials.gov registry entry for NCT00926120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mogroside sweetener (PureLo) is the first listed.
NCT00926120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926120 about?
NCT00926120 is a clinical study titled "The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC". The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.
What is the current status of trial NCT00926120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2008-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00926120?
The interventions under investigation include: Mogroside sweetener (PureLo) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00926120?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.